February 20, 2018
US Bioservices now dispenses ERLEADA
The U.S. Food and Drug Administration has approved ERLEADA (apalutamide) for non-metastatic castration-resistant prostate cancer.
We use cookies and tracking technologies to offer you a better browsing experience, analyze site traffic, and improve the website. By clicking “Accept Cookies”, you expressly agree to our use of cookies and tracking technologies in accordance with our Cookie Policy. If you wish to prevent your data from being used by Google Analytics you can opt-out below.
Coronavirus (COVID-19) Update
AmerisourceBergen and our global businesses are highly engaged during the ongoing spread of the novel COVID-19 “Coronavirus."